Current and future options in cholesterol lowering treatments

Eur J Intern Med. 2023 Feb 20:S0953-6205(23)00050-X. doi: 10.1016/j.ejim.2023.02.010. Online ahead of print.ABSTRACTThe relative risk reduction of cardiovascular events is proportional to the absolute reduction in LDL-C levels, the primary target of therapy, no matter the way of reduction. During the last decades, the therapeutic regimens for reducing the LDL-C levels have been immerged and improved, with favorable effects on the atherosclerotic process and clinical benefits of various cardiovascular outcomes. From a practical view of point, this review is focusing only on the current available lipid lowering agents: statins, ezetimibe, anti PCSK9 monoclonal antibodies, the small interfering RNA (siRNA) agent, Inclisiran, and Bempedoic acid. The recent changes in lipid lowering regimens, including the early combination of lipid lowering agents and "Low LDL-C" levels <30 mg/dL for high/very high cardiovascular risk patients will also be discussed.PMID:36813611 | DOI:10.1016/j.ejim.2023.02.010

Source: European Journal of Internal Medicine - February 22, 2023 Category: Internal Medicine Authors: Avishay Elis Source Type: research